2024-05-09 10:13
Jefferies issued a research report saying that WUXI BIO (02269.HK) +0.720 (+5.099%) Short selling $29.50M; Ratio 5.798% is now at an inflection point from a PB ratio perspective, and believing that its risk and reward profile is tipping towards more upside than downside. Therefore, Jefferies rated WUXI BIO at Buy, with a target price of $53.
Investors are coming to a consensus on the geopolitical issues faced by WUXI BIO, Jefferies added. As the US Biosecure Act progresses, there will be more clarity to come, especially on how existing contracts will be handled.
(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2024-05-08 16:25.)
Related NewsCMS Downgrades WUXI BIO (02269.HK) to Neutral, Slashes TP to $13
AAStocks Financial News
IHSG Melemah ke 7.083 Selasa (14/5), TPIA, BBCA, TLKM Paling Banyak Net Buy Asing
Asing Net Sell Jumbo Rp 2 Triliun di Awal Pekan, TAPG & BBRI Paling Banyak Dilepas
Saham BBRI Stagnan, ASII dan SMGR Memerah di Penutupan Bursa Senin (13/5)
GoTo Gojek (GOTO) Divestasi GoSend Senilai Rp 14,7 Miliar
Periksa kapanpun Anda mau
WikiStock APP